Gilead Sciences (NASDAQ:GILD) turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter.

The difference in earnings was even starker: Adjusted EPS of $2.36 beat analyst expectations by a whopping 31% and quadrupled the year-ago quarter.

Yet shares today were flat.

In the video below, health care analysts Michael Douglass and David Williamson give more detail on Gilead's great quarter.